George C Ebers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9465604/publications.pdf

Version: 2024-02-01

211 papers	26,620 citations	16437 64 h-index	5986 160 g-index
213 all docs	213 docs citations	213 times ranked	16672 citing authors

#	Article	IF	Citations
1	New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Annals of Neurology, 1983, 13, 227-231.	2.8	7,193
2	Randomised double-blind placebo-controlled study of interferon Î²-1a in relapsing/remitting multiple sclerosis. Lancet, The, 1998, 352, 1498-1504.	6.3	1,968
3	Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurology, The, 2006, 5, 932-936.	4.9	785
4	A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Research, 2010, 20, 1352-1360.	2.4	737
5	A full genome search in multiple sclerosis. Nature Genetics, 1996, 13, 472-476.	9.4	638
6	A Population-Based Study of Multiple Sclerosis in Twins. New England Journal of Medicine, 1986, 315, 1638-1642.	13.9	579
7	The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain, 2010, 133, 1914-1929.	3.7	563
8	Environmental factors and multiple sclerosis. Lancet Neurology, The, 2008, 7, 268-277.	4.9	519
9	Genetics of multiple sclerosis. Lancet Neurology, The, 2004, 3, 104-110.	4.9	458
10	Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D. PLoS Genetics, 2009, 5, e1000369.	1.5	442
11	Twin concordance and sibling recurrence rates in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12877-12882.	3.3	433
12	The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease. Brain, 2006, 129, 584-594.	3.7	393
13	Timing of birth and risk of multiple sclerosis: population based study. BMJ: British Medical Journal, 2005, 330, 120.	2.4	380
14	Evidence for genetic basis of multiple sclerosis. Lancet, The, 1996, 347, 1728-1730.	6.3	321
15	Genomeâ€wide metaâ€analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology, 2011, 70, 897-912.	2.8	314
16	A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nature Medicine, 2010, 16, 1157-1160.	15.2	312
17	Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nature Genetics, 1993, 3, 305-310.	9.4	311
18	A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nature Genetics, 2005, 37, 1108-1112.	9.4	295

#	Article	IF	Citations
19	Review: The role of vitamin <scp>D</scp> in nervous system health and disease. Neuropathology and Applied Neurobiology, 2013, 39, 458-484.	1.8	277
20	Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet, The, 2003, 361, 545-552.	6.3	276
21	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 436-445.	4.9	267
22	Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet, The, 2004, 363, 1773-1774.	6.3	249
23	Male Homosexuality: Absence of Linkage to Microsatellite Markers at Xq28. Science, 1999, 284, 665-667.	6.0	232
24	Environmental factors and their timing in adult-onset multiple sclerosis. Nature Reviews Neurology, 2010, 6, 156-166.	4.9	228
25	Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain, 2004, 127, 1009-1018.	3.7	226
26	Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. American Journal of Clinical Nutrition, 2008, 88, 441-447.	2.2	223
27	Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Human Molecular Genetics, 2005, 14, 2019-2026.	1.4	212
28	The contribution of demyelination to axonal loss in multiple sclerosis. Brain, 2006, 129, 1507-1516.	3.7	209
29	Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Annals of Neurology, 2011, 70, 881-886.	2.8	204
30	Mortality in patients with multiple sclerosis. Neurology, 2013, 81, 184-192.	1.5	199
31	Epigenetics: molecular mechanisms and implications for disease. Trends in Molecular Medicine, 2010, 16, 7-16.	3.5	180
32	The role of genetic factors in multiple sclerosis susceptibility. Journal of Neuroimmunology, 1994, 54, 1-17.	1.1	178
33	Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nature Genetics, 2008, 40, 1402-1403.	9.4	173
34	The extent of axonal loss in the long tracts in hereditary spastic paraplegia. Neuropathology and Applied Neurobiology, 2004, 30, 576-584.	1.8	156
35	Epistasis amongHLA-DRB1, HLA-DQA1,andHLA-DQB1loci determines multiple sclerosis susceptibility. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7542-7547.	3.3	148
36	Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurology, The, 2007, 6, 604-610.	4.9	145

#	Article	IF	Citations
37	Multiple sclerosis: the environment and causation. Current Opinion in Neurology, 2007, 20, 261-268.	1.8	143
38	Clinical prognostic factors in multiple sclerosis: a natural history review. Nature Reviews Neurology, 2009, 5, 672-682.	4.9	138
39	Genetics of multiple sclerosis [published erratum appears in Hum Mol Genet 1997 Nov;6(12):2189]. Human Molecular Genetics, 1997, 6, 1693-1698.	1.4	134
40	An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20896-20901.	3.3	122
41	Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. Genes and Immunity, 2010, 11, 99-112.	2.2	122
42	Month of birth, vitamin D and risk of immune-mediated disease: a case control study. BMC Medicine, 2012, 10, 69.	2.3	118
43	The Inheritance of Resistance Alleles in Multiple Sclerosis. PLoS Genetics, 2007, 3, e150.	1.5	109
44	Mapping the gene for acetazolamide responsive hereditary paryoxysmal cerebellar ataxia to chromosome 19p. Human Molecular Genetics, 1995, 4, 279-284.	1.4	102
45	Interferon in relapsing-remitting multiple sclerosis. The Cochrane Library, 2001, , CD002002.	1.5	91
46	Genetic, environmental and stochastic factors in monozygotic twin discordance with a focus on epigenetic differences. BMC Medicine, 2012, 10, 93.	2.3	90
47	Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Human Molecular Genetics, 2008, 18, 261-266.	1.4	89
48	Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 126-138.	1.4	88
49	Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis. JAMA Neurology, 2013, 70, 214.	4.5	88
50	Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon Î²-1b trial in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 282-287.	0.9	87
51	HLA class I alleles tag HLA-DRB1 * 1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13069-13074.	3.3	86
52	Age of puberty and the risk of multiple sclerosis: a population based study. European Journal of Neurology, 2009, 16, 342-347.	1.7	86
53	Association of Infectious Mononucleosis with Multiple Sclerosis. Neuroepidemiology, 2009, 32, 257-262.	1.1	85
54	Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology, 2010, 74, 1905-1910.	1.5	85

#	Article	IF	Citations
55	The Multiple Sclerosis Risk Sharing Scheme Monitoring Study â€“ early results and lessons for the future. BMC Neurology, 2009, 9, 1.	0.8	84
56	Functional analysis of missense variants in the TRESK (KCNK18) K+ channel. Scientific Reports, 2012, 2, 237.	1.6	82
57	Multiple sclerosis and the major histocompatibility complex. Current Opinion in Neurology, 2009, 22, 219-225.	1.8	77
58	Significant linkage to migraine with aura on chromosome 11q24. Human Molecular Genetics, 2003, 12, 2511-2517.	1.4	76
59	Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. Journal of Neurology, 2000, 247, 376-382.	1.8	75
60	Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Annals of Neurology, 1992, 32, 643-650.	2.8	74
61	Evidence of Linkage with HLA-DR in DRB1*15-Negative Families with Multiple Sclerosis. American Journal of Human Genetics, 2001, 69, 900-903.	2.6	72
62	EVI5 is a risk gene for multiple sclerosis. Genes and Immunity, 2008, 9, 334-337.	2.2	72
63	Bone marrow transplantation in multiple sclerosis. Journal of Neurology, 2000, 247, 691-695.	1.8	67
64	Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. Journal of Human Genetics, 2009, 54, 676-680.	1.1	65
65	Susceptibility to multiple sclerosis: interplay between genes and environment. Current Opinion in Neurology, 2000, 13, 241-247.	1.8	64
66	Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 793-795.	0.9	64
67	Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. Journal of the Neurological Sciences, 2011, 305, 116-120.	0.3	61
68	Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans. Genome Research, 2012, 22, 2138-2145.	2.4	61
69	Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. BMC Medicine, 2013, 11, 163.	2.3	59
70	Maternal Transmission of Multiple Sclerosis in a Dutch Population. Archives of Neurology, 2008, 65, 345-8.	4.9	58
71	Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends in Neurosciences, 2008, 31, 645-652.	4.2	57
72	Sex ratio of multiple sclerosis and clinical phenotype. European Journal of Neurology, 2010, 17, 634-637.	1.7	57

#	Article	IF	Citations
73	Interferon beta for secondary progressive multiple sclerosis. The Cochrane Library, 2012, 1, CD005181.	1.5	57
74	Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology, 2012, 79, 406-411.	1.5	56
75	Genetics of Multiple Sclerosis. Seminars in Neurology, 1998, 18, 295-299.	0.5	55
76	Natural history of primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, S8-S15.	1.4	55
77	Genomewide Study of Multiple Sclerosis. New England Journal of Medicine, 2007, 357, 2199-2201.	13.9	54
78	Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet, The, 1991, 337, 1540-1541.	6.3	52
79	An extended genome scan in 442 Canadian multiple sclerosis-affected sibships: a report from the Canadian Collaborative Study Group. Human Molecular Genetics, 2004, 13, 1005-1015.	1.4	52
80	Multiple sclerosis and birth order: a longitudinal cohort study. Lancet Neurology, The, 2005, 4, 611-617.	4.9	52
81	A Role for VAV1 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Science Translational Medicine, 2009, 1, 10ra21.	5.8	52
82	Genetic and environmental factors and the distribution of multiple sclerosis in Europe. European Journal of Neurology, 2010, 17, 1210-1214.	1.7	52
83	Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Human Molecular Genetics, 2012, 21, 3575-3586.	1.4	50
84	Interferons in the Treatment of Multiple Sclerosis. Archives of Neurology, 1998, 55, 1578.	4.9	49
85	The genetics of clinical outcome in multiple sclerosis. Journal of Neuroimmunology, 2008, 201-202, 183-199.	1.1	49
86	Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Medicine, 2009, 1, 105.	3.6	48
87	Genetic Factors in Multiple Sclerosis. Neurologic Clinics, 1983, 1, 645-654.	0.8	47
88	Genetic counselling in multiple sclerosis: risks to sibs and children of affected individuals. Clinical Genetics, 1999, 56, 118-122.	1.0	47
89	Parental transmission of HLA-DRB1*15 in multiple sclerosis. Human Genetics, 2008, 122, 661-663.	1.8	47
90	Interferon Â for secondary progressive multiple sclerosis: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 420-426.	0.9	47

#	Article	IF	Citations
91	T cell receptor Î± chain polymorphisms in multiple sclerosis. Journal of Neuroimmunology, 1992, 40, 41-48.	1.1	46
92	Treatment of multiple sclerosis. Lancet, The, 1994, 343, 275-279.	6.3	46
93	Prognostic factors for multiple sclerosis: the importance of natural history studies. Journal of Neurology, 2005, 252, iii15-iii20.	1.8	45
94	Hand Preference and Performance in 20 Pairs of Monozygotic Twins with Discordant Handedness. Cortex, 2006, 42, 934-945.	1.1	45
95	PRKCA and Multiple Sclerosis: Association in Two Independent Populations. PLoS Genetics, 2006, 2, e42.	1.5	45
96	No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study. Journal of Neuroimmunology, 2002, 123, 193-198.	1.1	44
97	Seasonal Distribution of Psychiatric Births in England. PLoS ONE, 2012, 7, e34866.	1.1	43
98	Association between microchimerism and multiple sclerosis in Canadian twins. Journal of Neuroimmunology, 2006, 179, 145-151.	1.1	41
99	Genes for multiple sclerosis. Lancet, The, 2008, 371, 283-285.	6.3	41
100	MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS. Neurology, 2009, 73, 1932-1933.	1.5	41
101	Parent-of-origin effects at the major histocompatibility complex in multiple sclerosis. Human Molecular Genetics, 2010, 19, 3679-3689.	1.4	41
102	Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics, 2001, 3, 145-151.	0.7	40
103	Association of smoking with risk of multiple sclerosis: a population-based study. Journal of Neurology, 2013, 260, 1778-1781.	1.8	39
104	Immunoglobulin heavy chain variable region polymorphisms and multiple sclerosis susceptibility. Journal of Neuroimmunology, 1993, 44, 77-83.	1.1	37
105	Genetics of Multiple Sclerosis. Neurologic Clinics, 1995, 13, 99-118.	0.8	37
106	Cause of death in MS: long-term follow-up of a randomised cohort, 21â€…years after the start of the pivotal IFNÎ²-1b study. BMJ Open, 2012, 2, e001972.	0.8	37
107	Abnormalities in Iron Metabolism in Multiple Sclerosis. Canadian Journal of Neurological Sciences, 1989, 16, 184-186.	0.3	35
108	Long-term follow-up of the original interferon-Î²1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clinical Therapeutics, 2009, 31, 1724-1736.	1.1	35

#	Article	IF	Citations
109	Epistasis. Neurology, 2009, 72, 566-567.	1.5	34
110	Type 1 diabetes mellitus and multiple sclerosis: common etiological features. Nature Reviews Endocrinology, 2009, 5, 655-664.	4.3	34
111	Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium. Human Molecular Genetics, 2007, 16, 1951-1958.	1.4	33
112	Factors influencing sib risks for Multiple Sclerosis. Clinical Genetics, 2008, 58, 431-435.	1.0	33
113	Genetics and multiple sclerosis: An overview. Annals of Neurology, 1994, 36, S12-S14.	2.8	32
114	Vitamin Dâ€“gene interactions in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 32-36.	0.3	32
115	High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ, The, 2012, 344, e4212-e4212.	3.0	32
116	A genome-wide scan in forty large pedigrees with multiple sclerosis. Journal of Human Genetics, 2007, 52, 955-962.	1.1	30
117	Association studies in multiple sclerosis. Journal of Neuroimmunology, 1994, 53, 117-122.	1.1	29
118	Crossed cerebral lateralization for verbal and visuoâ€spatial function in a pair of handedness discordant monozygotic twins: MRI and fMRI brain imaging. Journal of Anatomy, 2008, 212, 235-248.	0.9	29
119	Prognosis of the individual course of disease: the elements of time, hetereogeneity and precision. Journal of the Neurological Sciences, 2009, 287, S50-S55.	0.3	29
120	Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Multiple Sclerosis Journal, 2010, 16, 147-155.	1.4	29
121	Progress in deciphering the genetics of multiple sclerosis. Current Opinion in Neurology, 2003, 16, 253-258.	1.8	28
122	An Array of Sunshine in Multiple Sclerosis. New England Journal of Medicine, 2002, 347, 1445-1447.	13.9	27
123	Multiple sclerosis susceptibility and the X chromosome. Multiple Sclerosis Journal, 2007, 13, 856-864.	1.4	26
124	Age of Onset in Concordant Twins and Other Relative Pairs With Multiple Sclerosis. American Journal of Epidemiology, 2009, 170, 289-296.	1.6	26
125	Reducing the probability of false positive research findings by pre-publication validation â€“ Experience with a large multiple sclerosis database. BMC Medical Research Methodology, 2008, 8, 18.	1.4	25
126	No evidence for an effect of DNA methylation on multiple sclerosis severity at HLA-DRB1*15 or HLA-DRB5. Journal of Neuroimmunology, 2010, 223, 120-123.	1.1	25

#	Article	IF	Citations
127	A genome-wide scan of male sexual orientation. Journal of Human Genetics, 2010, 55, 131-132.	1.1	25
128	Microchimerism in autoimmunity and transplantation: potential relevance to multiple sclerosis. Journal of Neuroimmunology, 2002, 126, 126-133.	1.1	24
129	Interactions of environment and genes in multiple sclerosis. Journal of the Neurological Sciences, 2013, 334, 161-163.	0.3	24
130	A <scp>W</scp>ebâ€based tool for personalized prediction of longâ€term disease course in patients with multiple sclerosis. European Journal of Neurology, 2013, 20, 1107-1109.	1.7	24
131	TRPV1 Gates Tissue Access and Sustains Pathogenicity in Autoimmune Encephalitis. Molecular Medicine, 2013, 19, 149-159.	1.9	24
132	Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. Multiple Sclerosis Journal, 2014, 20, 1182-1188.	1.4	24
133	Seasonality of admissions with multiple sclerosis in Scotland. European Journal of Neurology, 2011, 18, 1109-1111.	1.7	23
134	Severe cerebellar degeneration in a patient with T-cell lymphoma. Acta Neuropathologica, 1986, 69, 171-175.	3.9	22
135	Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis. Brain, 2010, 133, 3470-3479.	3.7	22
136	The Epidemiology of Multiple Sclerosis in Scotland: Inferences from Hospital Admissions. PLoS ONE, 2011, 6, e14606.	1.1	21
137	Progress in deciphering the genetics of multiple sclerosis. Current Opinion in Neurology, 2003, 16, 253-258.	1.8	20
138	Preventing multiple sclerosis?. Lancet, The, 2001, 357, 1547.	6.3	19
139	Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis. Journal of Neurology, 2008, 255, 1215-1219.	1.8	19
140	Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis. Journal of Human Genetics, 2009, 54, 547-549.	1.1	19
141	Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 682-687.	0.9	19
142	Inactive or moderately active human promoters are enriched for inter-individual epialleles. Genome Biology, 2013, 14, R43.	13.9	19
143	Month of Birth and Thymic Output. JAMA Neurology, 2013, 70, 527.	4.5	19
144	Methylation of class II transactivator gene promoter IV is not associated with susceptibility to Multiple Sclerosis. BMC Medical Genetics, 2008, 9, 63.	2.1	18

#	Article	IF	Citations
145	An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1gene. BMC Medical Genetics, 2009, 10, 10.	2.1	18
146	fMRI and corpus callosum relationships in monozygotic twins discordant for handedness. Brain Structure and Function, 2013, 218, 491-509.	1.2	18
147	Osier and Neurology. Canadian Journal of Neurological Sciences, 1985, 12, 236-242.	0.3	17
148	Vitamin Dâ€"Dependent Rickets, HLA-DRB1, and the Risk of Multiple Sclerosis. Archives of Neurology, 2010, 67, 1034-5.	4.9	17
149	Role of the HLA System in the Association Between Multiple Sclerosis and Infectious Mononucleosis. Archives of Neurology, 2011, 68, 469.	4.9	17
150	Determination of the real effect of genes identified in GWAS: the example of IL2RA in multiple sclerosis. European Journal of Human Genetics, 2012, 20, 321-325.	1.4	17
151	Prevalence of MS in Iranian Immigrants to British Columbia, Canada. Journal of Neurology, 2010, 257, 667-668.	1.8	16
152	Exclusion of linkage between hypokalemic periodic paralysis (HOKPP) and three candidate loci. Genomics, 1992, 14, 493-494.	1.3	15
153	TCR Î² polymorphisms and multiple sclerosis. Genes and Immunity, 2004, 5, 337-342.	2.2	15
154	Follow-up investigation of 12 proposed linkage regions in multiple sclerosis. Genes and Immunity, 2006, 7, 366-371.	2.2	15
155	The role of hereditary spastic paraplegia related genes in multiple sclerosis. Journal of Neurology, 2007, 254, 1221-1226.	1.8	15
156	DNA methylation in monozygotic quadruplets affected by type 1 diabetes. Diabetologia, 2013, 56, 2093-2095.	2.9	15
157	A twin consensus in MS. Multiple Sclerosis Journal, 2005, 11, 497-499.	1.4	14
158	Clustering of autoimmune disease in families at high risk for multiple sclerosis?. Lancet Neurology, The, 2007, 6, 206-207.	4.9	14
159	Natural history of MS. European Journal of Neurology, 2008, 15, 881-882.	1.7	14
160	Chromosome 1p36 in migraine with aura. NeuroReport, 2012, 23, 45-48.	0.6	14
161	Disease evolution in multiple sclerosis. Journal of Neurology, 2006, 253, vi3-vi8.	1.8	13
162	No Effect of Birth Weight on the Risk of Multiple Sclerosis. Neuroepidemiology, 2008, 31, 181-184.	1.1	13

#	Article	IF	Citations
163	Month of Birth and Multiple Sclerosis Risk in Scotland. European Neurology, 2010, 63, 41-42.	0.6	13
164	No effect of preterm birth on the risk of multiple sclerosis: a population based study. BMC Neurology, 2008, 8, 30.	0.8	12
165	Mutations in the hemochromatosis gene and the clinical outcome of multiple sclerosis. Journal of Neuroimmunology, 2008, 203, 104-107.	1.1	12
166	Congenital Abnormalities and Multiple Sclerosis. BMC Neurology, 2010, 10, 115.	0.8	11
167	DE NOVO RELAPSING-REMITTING MULTIPLE SCLEROSIS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION. Neurology, 2010, 75, 89-91.	1.5	11
168	No Effect of Parental Age on Risk of Multiple Sclerosis: A Population-Based Study. Neuroepidemiology, 2010, 34, 106-109.	1.1	10
169	Relapses do not matter in relation to long-term disability: Yes. Multiple Sclerosis Journal, 2011, 17, 1412-1414.	1.4	10
170	Hexose-6-phosphate dehydrogenase: a new risk gene for multiple sclerosis. European Journal of Human Genetics, 2010, 18, 618-620.	1.4	9
171	Reply to â€œLack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosisâ€• Nature Genetics, 2010, 42, 470-471.	9.4	9
172	Revisiting the T-cell receptor alpha/delta locus and possible associations with multiple sclerosis. Genes and Immunity, 2011, 12, 59-66.	2.2	9
173	Protein-Protein Interaction Analysis Highlights Additional Loci of Interest for Multiple Sclerosis. PLoS ONE, 2012, 7, e46730.	1.1	9
174	Modelling multiple sclerosis. Nature Genetics, 1999, 23, 258-259.	9.4	8
175	No effect of APOE and PVRL2 on the clinical outcome of multiple sclerosis. Journal of Neuroimmunology, 2007, 186, 156-160.	1.1	8
176	Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 127-128.	1.4	8
177	Childhood cow's milk allergy and the risk of multiple sclerosis: A population based study. Journal of the Neurological Sciences, 2010, 291, 86-88.	0.3	8
178	Vitamin D and multiple sclerosis hospital admissions in Scotland. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 1001-1003.	0.2	8
179	Spinal Cord Swelling in Multiple Sclerosis. Canadian Journal of Neurological Sciences, 1981, 8, 151-153.	0.3	7
180	Heritability of serum vitamin D concentrations: twin studies. American Journal of Clinical Nutrition, 2011, 93, 667-668.	2.2	7

#	Article	IF	Citations
181	Maternal - offspring HLA-DRB1 compatibility in multiple sclerosis. Tissue Antigens, 2005, 66, 44-47.	1.0	6
182	Microsatellites and genome scans â€" A GAMES postscript. Journal of Neuroimmunology, 2007, 190, 5-7.	1.1	6
183	Gestational Diabetes and Multiple Sclerosis. Epidemiology, 2009, 20, 783-784.	1.2	6
184	HLAâ€DRB1*15, low infant sibling exposure, and multiple sclerosis geneâ€"environment interaction. Annals of Neurology, 2010, 67, 694-695.	2.8	5
185	MS and autoimmune disorders. Neurogenetics, 2009, 10, 1-3.	0.7	5
186	IGHV4-39 deletion polymorphism does not associate with risk or outcome of multiple sclerosis. Journal of Neuroimmunology, 2010, 225, 164-166.	1.1	5
187	Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS. Neurology, 2011, 76, 1025-1026.	1.5	5
188	Interferons in relapsing remitting multiple sclerosis. Lancet, The, 2003, 361, 1823-1824.	6.3	4
189	Origins of magic: review of genetic and epigenetic effects. BMJ: British Medical Journal, 2007, 335, 1299-1301.	2.4	4
190	A first stage genomeâ€wide screen for regions shared identicalâ€byâ€descent in hutterite families with multiple sclerosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 467-472.	1.1	4
191	Editorial regarding â€œExplaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis,â€•by Beretich and Beretich. Multiple Sclerosis Journal, 2009, 15, 889-890.	1.4	4
192	William Osler (1849â€"1919). Journal of Neurology, 2006, 253, 127-128.	1.8	3
193	Parental non-inherited HLA resistance alleles do not confer protection against multiple sclerosis. Journal of Neuroimmunology, 2008, 196, 170-172.	1.1	3
194	Autoimmune disease in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Multiple Sclerosis Journal, 2008, 14, 1288-1289.	1.4	3
195	Early life child exposure and the risk of multiple sclerosis: A population based study. Journal of the Neurological Sciences, 2011, 307, 162-163.	0.3	3
196	Robert Whytt, Benjamin Franklin, and the first probable case of multiple sclerosis. Annals of Neurology, 2012, 72, 307-311.	2.8	3
197	Reducing the Probability of False Positive Research Findings by Pre-Publication Validation - Experience with a Large Multiple Sclerosis Database. Nature Precedings, 2007, , .	0.1	2
198	Passive smoking and replication. European Journal of Neurology, 2008, 15, 1263-1264.	1.7	2

#	Article	IF	Citations
199	Sequencing the multiple sclerosis genome: more questions than answers. Lancet Neurology, The, 2010, 9, 757-759.	4.9	2
200	Predicting a window of therapeutic opportunity in multiple sclerosis. Brain, 2010, 133, e162-e162.	3.7	2
201	Combined MRI Lesions and Relapses as a Surrogate for Disability in MS. Neurology, 2012, 78, 1367-1367.	1.5	2
202	Chapter 3 Natural History of Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 21-32.	0.1	1
203	Variants in ST8SIA1 do not play a major role in susceptibility to multiple sclerosis in Canadian families. Journal of Neuroimmunology, 2009, 212, 142-144.	1.1	1
204	Motherâ€“child blood group incompatibility and the risk of multiple sclerosis. Journal of Neurology, 2010, 257, 286-287.	1.8	1
205	MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No. Multiple Sclerosis Journal, 2014, 20, 282-283.	1.4	1
206	Birth order, infection in early life, and multiple sclerosis â€“ Authors' reply. Lancet Neurology, The, 2005, 4, 795.	4.9	0
207	Teaching Video Neuro Image :The â€œFonzarelliâ€•sign. Neurology, 2008, 71, e11.	1.5	0
208	Gene associations â€” SNPs and function. Journal of Neuroimmunology, 2011, 232, 3-4.	1.1	0
209	Tasmania: state of MS in Australia. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 119-119.	0.9	0
210	Reply to Oluf Anderson's Reply: Predicting a window of therapeutic opportunity in multiple sclerosis. Brain, 2011, 134, e175-e175.	3.7	0
211	Suppressor Alleles in Multiple Sclerosis: Inheritance and Interactions. PLoS Genetics, 2005, preprint, e150.	1.5	0